Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

National University Hospital, Singapore3,000 enrolled

Overview

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Cardiovascular Diseases Metabolic Syndrome Non-Alcoholic Fatty Liver Disease

Interventions

Digital wearable and AI-human symbiotic lifestyle intervention

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 40-70 years old * ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher Exclusion Criteria: * Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke) * Limited life expectancy * Other ongoing unstable medical conditions * Pregnant women

Outcomes

Primary Outcomes

Major adverse cardiovascular event

Composite of cardiac death, non-fatal myocardial infarction, resuscitated cardiac arrest, non-fatal ischemic stroke, congestive heart failure, coronary revascularization

Time frame: 5 years